Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Context Therapeutics Inc.NASDAQ: CNTX
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $3.19M (cash outflow) rose 312.2% year over year, ahead of the +216.5% change in trailing-twelve-month change in working capital.
Context
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +312.2% holds above the trailing-twelve-month pace of +216.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 6.28M USD
- Year-over-year change
- +280.7%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.28M | +280.7% |
| FY2024 | 2024-12-31 | (3.48M) | -295.8% |
| FY2023 | 2023-12-31 | 1.78M | +739.8% |
| FY2022 | 2022-12-31 | (277.52K) | +87.5% |
| FY2021 | 2021-12-31 | (2.22M) | — |
Change in Working Capital vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +216.5% is the 4th highest of 10, against a peer median of +67.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMAImageneBio Inc | LTM Mar 2026 | $21.14M USD | +968.3% | +8.2% | — |
| LTM Mar 2026 | $17.87M USD | +67.2% | +66.6% | 11.4% | |
| LTM Mar 2026 | $15.66M USD | +595.3% | +26.5% | — | |
| LTM Mar 2026 | €8.45M EUR | +450.5% | — | 28812.5% | |
| LTM Mar 2026 | $4.28M USD | -7474.4% | +29.6% | 3191.9% | |
| LTM Mar 2026 | $3.86M USD | +216.5% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $1.93M USD | -48.2% | — | 27.0% |
| LTM Mar 2026 | $1.73M USD | -162.8% | -44.0% | 172.9% | |
| FY2025 | $580K USD | +103.7% | -56.7% | 906.3% | |
| LTM Mar 2026 | $469K USD | -263.4% | -20.7% | 6.6% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $53K USD | — | +0.3% | — |
| Peer median (excluding CNTX) | — | +67.2% | +4.3% | 172.9% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 511.08K | 976.44K | 1.08M | 841.87K | 1.33M |
| Change in Working Capital | (2.22M) | (277.52K) | 1.78M | (3.48M) | 6.28M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (866.01K) | (787.89K) | 1.45M | (946K) | 1.1M |
| Other Working Capital | (1.36M) | 510.37K | 329.03K | (2.53M) | 5.19M |
| Other Non-Cash Items | 3.37M | 578.52K | 51.97K | 14.79M | 2.11M |
| Operating Cash Flow | (8.8M) | (13.55M) | (21.05M) | (14.56M) | (26.39M) |
| Capital Expenditures | (250K) | (536.84K) | 0 | (14.76M) | (33.95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (14.75M) | (2M) |
| Investing Cash Flow | (250K) | (536.84K) | 0 | (14.76M) | (2.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 53.41M | (102.07K) | 0 | 109.29M | (15.27K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 58.39M | (102.07K) | 0 | 109.29M | (15.27K) |
| Effect of Forex Changes | 0 | 50.39K | 0 | 0 | 0 |
| Net Change in Cash | 49.34M | (14.14M) | (21.05M) | 79.98M | (28.43M) |
| Free Cash Flow | (9.05M) | (14.09M) | (21.05M) | (29.31M) | (26.42M) |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.